Eight real-world analyses regarding Entyvio (vedolizumab) for treating adults with moderate to severe ulcerative colitis (UC) and Crohn's disease (CD) were presented at the 2017 Digestive Disease Week (DDW) annual scientific meeting.
Takeda Pharmaceutical Co. announced the data on May 8.
The real-world data is being generated by a consortium of 10 leading inflammatory bowel disease (IBD) centers in the U.S. The VICTORY consortium has collected clinical information on approximately 900 UC and CD patients in the database.
Abstract No. 1853 features a cohort analysis from the consortium in patients treated with vedolizumab. The data included the responses and remissions in 180 patients with UC. Seventy-seven percent achieved mucosal healing, while 51 percent achieved clinical remission and 41 percent achieved steroid-free remission.
“The real-world evidence from the VICTORY consortium supports the data observed in the pivotal GEMINI clinical trial program, further demonstrating the effectiveness of vedolizumab,” University of California San Diego Research Fellow and Lead Investigator of the VICTORY consortium analyses Dr. Parambir Dulai said.
Takeda presented other posters, including evaluations of the long-term effectiveness and safety of Entyvio, and analysis of the GEMINI I and II study data. The Phase III clinical trials recruited 2,400 individuals from 40 countries.